Overview

• In a UCLA-led phase 1 study of 25 post‑surgery patients, 21 generated KRAS‑specific T cells after receiving the ELI‑002 2P vaccine.
• Median relapse‑free survival reached about 16 months and overall survival about 28 months, surpassing historical expectations for these cancers.
• Patients with the strongest KRAS‑specific responses saw the greatest benefit, and 67% also mounted responses to additional tumor‑associated mutations.
• KRAS mutations drive roughly half of colorectal cancers and more than 90% of pancreatic cancers, providing a clear rationale for this targeted approach.
• Investigators are advancing a broader candidate, ELI‑002 7P, with larger follow‑up trials planned to evaluate whether the immune signals translate into clinical benefit.